KRAS and neoplasm: The adoptive transfer of T-cells harbouring the engineered T-cell receptors (TCR) that specifically recognise mutated KRAS variants G12V and G12D has also been proven effective in reducing tumour growth in a KRAS mutant xenograft model [24].